Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$12.87 -4.4%	$14.31	$8.24 ▼ $18.38	$877.26M	-0.29	683,616 shs	563,298 shs
NTLA Intellia Therapeutics	$11.46 +0.8%	$10.47	$5.90 ▼ $24.16	$1.18B	2.31	4.55 million shs	5.83 million shs
PLX Protalix BioTherapeutics	$1.51 +2.0%	$1.49	$0.82 ▼ $3.10	$117.82M	-0.21	851,583 shs	625,995 shs
SYRE Spyre Therapeutics	$15.24 -4.5%	$16.26	$10.91 ▼ $40.26	$962M	2.82	557,872 shs	417,085 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	-4.38%	-9.05%	-7.74%	-12.15%	+14.10%
NTLA Intellia Therapeutics	+0.79%	-1.55%	+3.06%	+41.13%	-46.22%
PLX Protalix BioTherapeutics	+2.03%	+3.42%	+2.03%	-12.21%	+51.00%
SYRE Spyre Therapeutics	-4.51%	-10.19%	-2.37%	+8.09%	-37.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	2.7994 of 5 stars	3.4	1.0	0.0	3.9	4.2	0.0
NTLA Intellia Therapeutics	4.6001 of 5 stars	4.3	2.0	4.7	3.2	2.5	0.6
PLX Protalix BioTherapeutics	2.4216 of 5 stars	3.5	3.0	0.0	0.6	0.0	1.9
SYRE Spyre Therapeutics	2.4558 of 5 stars	3.6	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	150.58% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	191.17% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	893.38% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	250.39% Upside

Current Analyst Ratings Breakdown

Latest PLX, SYRE, MLYS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NTLA Intellia Therapeutics	$57.88M	20.51	N/A	N/A	$8.56 per share	1.34
PLX Protalix BioTherapeutics	$59.76M	2.01	$0.08 per share	17.80	$0.47 per share	3.21
SYRE Spyre Therapeutics	$890K	1,032.21	N/A	N/A	$4.98 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.87	N/A	-21.03%	-30.89%	-11.74%	N/A
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	N/A

Latest PLX, SYRE, MLYS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.98	+$0.05	-$0.98	$12.26 million	$14.25 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	26.48	26.48
NTLA Intellia Therapeutics	N/A	4.90	4.90
PLX Protalix BioTherapeutics	N/A	1.98	1.27
SYRE Spyre Therapeutics	N/A	6.49	8.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
NTLA Intellia Therapeutics	88.77%
PLX Protalix BioTherapeutics	16.53%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	25.56%
NTLA Intellia Therapeutics	3.10%
PLX Protalix BioTherapeutics	6.50%
SYRE Spyre Therapeutics	15.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	50.98 million	Optionable

PLX, SYRE, MLYS, and NTLA Headlines

Recent News About These Companies

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

August 7 at 12:36 PM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

August 6 at 4:18 PM | marketbeat.com

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5 at 4:02 PM | globenewswire.com

TD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 5 at 3:44 AM | marketbeat.com

Jefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 2, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 1, 2025 | globenewswire.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

July 28, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by Analysts

July 17, 2025 | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16, 2025 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?

July 15, 2025 | marketbeat.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know

May 30, 2025 | zacks.com

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, SYRE, MLYS, and NTLA Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$12.87 -0.59 (-4.38%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$13.30 +0.44 (+3.38%)

As of 08/7/2025 06:09 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Intellia Therapeutics NASDAQ:NTLA

$11.46 +0.09 (+0.79%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$11.80 +0.34 (+2.98%)

As of 04:05 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$1.51 +0.03 (+2.03%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$1.52 +0.01 (+0.99%)

As of 08/7/2025 06:03 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Spyre Therapeutics NASDAQ:SYRE

$15.24 -0.72 (-4.51%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$15.24 0.00 (0.00%)

As of 08/7/2025 07:36 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time